Clinical Trials
14 trialsNCT05322330 2026-06-02
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Completed
NCT07593482 2026-05-18
FC-BALANCE
Swiss Cancer Institute
Phase 2 Not yet recruiting
NCT07569965 2026-05-06
FRONTIER
Miltenyi Biomedicine GmbH
Phase 2 Not yet recruiting
NCT05583149 2026-01-29
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT05972720 2025-05-15
FIRCE-1
CARGO Therapeutics
Phase 2 Terminated
NCT04792489 2025-04-24
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT03761056 2024-12-04
ZUMA-12
Gilead Sciences
Phase 2 Completed
NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT02661035 2023-09-21
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT04121507 2023-05-24
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
GWT-TUD GmbH
Phase 2 Completed
NCT01434472 2021-07-20
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00946023 2018-08-27
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT02718755 2018-06-26
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
M.D. Anderson Cancer Center
Phase 2 Withdrawn